

Supplementary Table 1: Disease Stage by Clinical Response

	IIIB	IIIC	IV1a	IV1b	IV1c	IV1d
CR	11	8	2	0	0	0
MLR	3	6	1	0	0	0
LCDP	3	4	2	0	0	1
NR	5	7	6	5	1	4
Total Patients Treated	22	25	11	5	1	5

Supplementary Table 2: Description of T-VEC Treatment by Clinical Response

	Median number of total doses (range)	Multiple courses of TVEC?	Prior wide local excision?	Prior exposure to systemic therapy?	Concurrent systemic therapy?	Received T-VEC as upfront therapy	Received T-VEC for new disease developed <8 weeks following surgery
CR	6 (3-19)	1/21	18/21	6/21	5/21	3/21	1/21
MLR	11 (3-27)	2/10	10/10	5/10	0/10	0/10	1/10
LCDP	8 (3-19)	1/10	10/10	4/10	2/10	0/10	1/10
NR	4 (2-12)	0/28	24/28	17/28	11/28	2/28	2/28
Total Patients Treated	5 (2-27)	4/69	63/69	32/69	18/69	5/69	5/69

Supplementary Table 3: Tumor Location by Clinical Response

	Head and Neck	UE	LE	Trunk	Unknown
CR	7	3	10	1	0
MLR	2	0	7	1	0
LCDP	1	0	8	1	0
NR	6	2	13	4	3
Total Patients Treated	16/69	5/69	38/69	7/69	3/69

Supplementary Table 4: Tissue Origin of SNAPSHOT Data

<u>Tissue Origin</u>	<u>Number of Patients</u>
Primary tumor	11
In transit metastases	32
Metastatic lymph node	6
Distant soft tissue metastases	5
Total Patients with SNAPSHOT Data Available	54

Supplementary Figure 1: Clinical Response of Head and Neck Tumors by Stage

